Welcome to our dedicated page for Tenon Medical SEC filings (Ticker: TNONW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Tenon Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Tenon Medical's regulatory disclosures and financial reporting.
Tenon Medical, Inc. reported strong top-line growth but continued losses for the quarter ended June 30, 2026. Revenue was $1.3 million, up 127% from the prior-year quarter, driven by a higher number of surgical procedures and added revenue from the SImmetry®+ System. Gross profit rose to $0.8 million with a 64% gross margin, compared with 43% a year earlier, reflecting higher volume and better absorption of fixed production costs.
Operating expenses increased to $4.2 million, mainly from higher sales and marketing spending for commercial expansion and SImmetry®+ rollout, and greater research and development investment. Net loss widened to $4.1 million (basic and diluted loss of $12.35 per share). Cash and cash equivalents were $1.7 million at June 30, 2026, versus $3.8 million at year-end, while current liabilities rose sharply and stockholders’ equity moved to a $1.7 million deficit.
Subsequent to quarter end, Tenon closed a public offering with $4.2 million in gross proceeds and approximately $3.6 million in net proceeds, intended in part to repay outstanding $5.2 million convertible notes maturing September 11, 2026 (extendable to December 11, 2026). The company also received FDA 510(k) clearance for an updated Catamaran® SI Joint Fusion System and highlighted record monthly case volume in July 2026. Forward-looking language cites risks including its ability to continue as a going concern, raise additional capital, and maintain Nasdaq listing compliance.
Tenon Medical, Inc. filed a Form S-3 shelf registration that permits the company to offer and sell, from time to time, up to $100,000,000 of common stock, preferred stock, warrants, debt securities, rights, or units. The filing also includes an at-the-market program to sell up to $4,397,821 of common stock through A.G.P./Alliance Global Partners. Pursuant to General Instruction I.B.6, primary offerings are limited to one-third of Tenon’s public float. As of August 10, 2026, public float was $13,193,463, based on 606,596 non-affiliate shares. Auditors’ reports on 2025 and 2024 financial statements include an explanatory paragraph about substantial doubt regarding Tenon’s ability to continue as a going concern.
Tenon Medical, Inc. approved and implemented a 1-for-35 reverse stock split of its common stock. A Certificate of Amendment was filed in Delaware on August 6, 2026, and the split became effective at 12:01 a.m. Eastern Time on August 10, 2026.
Every 35 shares of issued and outstanding common stock were automatically combined into one share, with fractional shares rounded up to the next whole share. The common stock continues to trade on the Nasdaq Capital Market under the symbol "TNON", with a new CUSIP number 88066N402.
Proportionate adjustments were made to stock options, warrants, equity plan reserves and restricted stock units. The company stated that the primary goal of the reverse split is to increase the per share market price of its common stock to meet the $1.00 average closing price requirement for continued listing on the Nasdaq Capital Market.
Tenon Medical, Inc. director Robert K. Weigle converted 10,732 Restricted Stock Units, granted on October 13, 2025, into 10,732 shares of common stock on July 31, 2026 at $0.00 per share. After this RSU conversion, he directly held 18,284 shares of Tenon Medical common stock.
Tenon Medical director Kristine M Jacques converted 10,147 restricted stock units, granted on October 13, 2025, into 10,147 shares of common stock on July 31, 2026. Following this RSU conversion, she directly holds 20,876 shares of Tenon Medical common stock.
Tenon Medical, Inc. director Ivan Howard exercised 10,732 restricted stock units on July 31, 2026, converting them into 10,732 shares of common stock at $0.00 per share. The RSUs were fully converted, and his direct ownership increased to 19,194 common shares after the transaction.
Tenon Medical, Inc. director Stephen Hochschuler converted 10,732 restricted stock units granted on October 13, 2025 into 10,732 shares of common stock on July 31, 2026 at a stated price of $0.00 per share. After the conversion, he directly holds 18,670 shares of Tenon Medical common stock and no remaining units from this grant.
Tenon Medical director Richard Ferrari converted 64,479 restricted stock units into 64,479 shares of common stock on July 31, 2026. Each unit represented a contingent right to receive one share. After this settlement, he directly owned 135,243 shares of Tenon Medical common stock.
Tenon Medical, Inc. Chief Financial Officer Kevin Williamson reported equity compensation activity and related tax withholding. On July 31, 2026, 58,987 restricted stock units vested and converted into 58,987 shares of common stock. On August 3, 2026, 12,978 common shares were delivered/withheld at $0.198 per share to satisfy tax liabilities arising from this RSU vesting.
Tenon Medical director and Chief Technology Officer Richard Ginn reported the vesting and conversion of 126,577 restricted stock units into the same number of common shares on July 31, 2026, from RSUs granted on October 13, 2025. On August 3, 2026, he sold 44,809 common shares at $0.198 per share to pay tax liability related to this RSU vesting.